University Clinic Bonn
Welcome,         Profile    Billing    Logout  
 1 Trial 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Skowasch, Dirk
NCT05243680 / 2020-004334-38: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Active, not recruiting
3
641
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
05/25
05/25
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1667
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
10/25
10/25
NCT06178341: Effects of the Kata® Inhalations-App on Inhaler Handling Errors, Adherence, and Asthma Control in Patients with Asthma.

Active, not recruiting
N/A
200
Europe
Kata Inhalations-App
VisionHealth GmbH, Thoraxklinik-Heidelberg gGmbH
Asthma
01/25
01/25
NCT06035289: Register Schweres Asthma - German Asthma Net e.V.

Recruiting
N/A
4500
Europe
German Asthma Net e.V., AstraZeneca, GlaxoSmithKline, Sanofi, Chiesi Farmaceutici S.p.A.
Severe Asthma
11/26
11/26
Weydt, Patrick
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
NCT05039099 / 2020-005971-11: A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Active, not recruiting
2
63
Europe, Canada, US, RoW
AP-101, Placebo
AL-S Pharma, AL-S Pharma
Amyotrophic Lateral Sclerosis
12/24
10/25

Download Options